HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.

Abstract
Patients with metastatic colorectal carcinoma (CRC) often develop bone metastases with a high risk of complications. Ibandronate is a novel single-nitrogen bisphosphonate that has been shown to be effective for treating bone metastases from breast cancer. A randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of ibandronate in patients with bone metastases from CRC. The primary efficacy end point was the proportion of patients with skeletal-related events (defined as pathologic fracture, spinal cord compression, radiation therapy to bone, change in antineoplastic therapy or surgery to bone). Secondary end points included time to first skeletal event, skeletal morbidity rate (events/year) and time to progression of bone lesions. In 73 patients with CRC, treatment with intravenous ibandronate 6 mg administered via a 15-min infusion significantly reduced the proportion of patients with skeletal events (39% vs. 78% with placebo; P = 0.019) and prolonged the time to first event by at least 6 months (median >279 vs. 93 days with placebo; P = 0.009). Ibandronate also significantly reduced the skeletal morbidity rate (mean 2.36 vs. 3.14 with placebo; P = 0.018) and prolonged time to progression of bone lesions (214 days vs. 81 days with placebo; P = 0.018). Ibandronate was well tolerated with very rare grade 3 or 4 toxicity. Furthermore, the incidence of renal adverse events was comparable with placebo and there were no clinically relevant changes in serum creatinine. Ibandronate provided significant clinical benefits for patients with bone metastases secondary to CRC. These results indicate that ibandronate may be an effective treatment for patients with metastatic bone disease following CRC. Larger studies are required for further assessment.
AuthorsP Heras, S Karagiannis, K Kritikos, A Hatzopoulos, D Mitsibounas
JournalEuropean journal of cancer care (Eur J Cancer Care (Engl)) Vol. 16 Issue 6 Pg. 539-42 (Nov 2007) ISSN: 0961-5423 [Print] England
PMID17944770 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Ibandronic Acid
Topics
  • Adult
  • Bone Density Conservation Agents (administration & dosage, therapeutic use)
  • Bone Neoplasms (prevention & control, secondary)
  • Colorectal Neoplasms
  • Diphosphonates (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Ibandronic Acid
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Pilot Projects

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: